Form 4: HealthEquity EVP Delano Ladd Sells 7,500 Shares

HealthEquity, Inc. EVP and General Counsel Delano Ladd sold 7,500 shares of common stock via a Rule 10b5-1 trading plan.

Summary

• Delano Ladd, EVP and General Counsel of HealthEquity, Inc., sold 7,500 shares of common stock.
• The transaction occurred on May 28, 2026, at a price of $90.00 per share.
• Following the sale, the reporting person retains beneficial ownership of 91,141 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 plan, which is a standard mechanism for executive financial planning.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future stock performance, though this was a pre-planned sale.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

HealthEquity, HQY, Insider Trading, Form 4, Executive Compensation, Stock Sale